These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 26427667)
21. GATA6: a new predictor for prognosis in ovarian cancer. Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927 [TBL] [Abstract][Full Text] [Related]
22. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566 [TBL] [Abstract][Full Text] [Related]
23. Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812 [TBL] [Abstract][Full Text] [Related]
24. [Expression of folate receptor alpha in ovarian epithelial tumors]. Shen DH; Xie JL; Zhang YL; Wang Y Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165 [TBL] [Abstract][Full Text] [Related]
25. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273 [TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150 [TBL] [Abstract][Full Text] [Related]
27. RING finger protein 187 as a novel potential biomarker for predicting the prognosis of ovarian carcinoma in 2 cancer centers. Chen J; Chen K; Zhou Z; Huang L; Cai Y; Tu H; Zhang X Curr Probl Cancer; 2020 Oct; 44(5):100555. PubMed ID: 32057463 [TBL] [Abstract][Full Text] [Related]
28. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma. Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467 [TBL] [Abstract][Full Text] [Related]
29. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500 [TBL] [Abstract][Full Text] [Related]
30. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. Szubert S; Szpurek D; Moszynski R; Nowicki M; Frankowski A; Sajdak S; Michalak S J Cancer Res Clin Oncol; 2014 Mar; 140(3):361-9. PubMed ID: 24374756 [TBL] [Abstract][Full Text] [Related]
31. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Yoshida A; Sarian LO; Andrade LA; Pignataro F; Pinto GA; Derchain SF Int J Gynecol Cancer; 2007; 17(3):607-14. PubMed ID: 17504375 [TBL] [Abstract][Full Text] [Related]
32. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway. Yousif HMA; Mohammed RAA Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260 [TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL Int J Gynecol Cancer; 2004; 14(5):815-23. PubMed ID: 15361189 [TBL] [Abstract][Full Text] [Related]
34. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407 [TBL] [Abstract][Full Text] [Related]
36. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. Wei W; Mok SC; Oliva E; Kim SH; Mohapatra G; Birrer MJ J Clin Invest; 2013 Oct; 123(10):4435-48. PubMed ID: 24018557 [TBL] [Abstract][Full Text] [Related]
38. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours. Saied EM; El-Etreby NM Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363 [TBL] [Abstract][Full Text] [Related]
39. [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma]. Chen AP; Zhang J; Liu H; Zhao SP; Dai SZ; Sun XL Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):48-52. PubMed ID: 19538870 [TBL] [Abstract][Full Text] [Related]
40. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]